Celgene, bluebird Report Promising CAR-T Myeloma Study

Dec 10, 2017

Celgene and bluebird bio announced promising updated results from an ongoing Phase 1 clinical study of bb2121, an investigational anti-B-cell maturation antigen CAR-T cell therapy.

In a small, early stage study, more than half of patients with advanced multiple myeloma who had run out of therapeutic options remained in complete remission after receiving the experimental gene-modifying immunotherapy being co-developed by Celgene and Cambridge, Massachusetts-based bluebird bio.

The first two CAR-T therapies from Novartis and Gilead Sciences were approved by the U.S. FDA this year to treat certain forms of blood cancers. The bluebird/Celgene therapy targets a different protein, BCMA, found on myeloma and plasma cells.

Due to the impressive results, Celgene plans to begin enrolling patients this month for a larger, potentially pivotal trial that could position bb2121 to become the third approved CAR-T.

Read the Reuters coverage
Read the press release


Show Comments
Hide Comments

Join the discussion

We welcome your thoughtful comments.
All comments will display your user name.

Want to participate in the discussion?

Register for free

Log in for complete access.


No one has commented on this page yet.

RSS feed for comments on this page | RSS feed for all comments